Syncona’s pre-clinical portfolio companies are developing their pipelines, proprietary platforms and progressing towards entering clinical trials.
Syncona’s pre-clinical portfolio comprises companies with a broad range of focuses including: repairing inflammatory organ damage, chronic renal diseases, induced pluripotent stem cell (iPSC)-derived medicines, oncology and protein homeostasis using a variety of modalities, including cell therapy, gene therapy and small molecules.
Key facts
Unless stated all financials at 30 June 2023
£137m
Value of pre-clinical portfolio
10
Labs
11
Portfolio company Board seats
The pre-clinical portfolio pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA